The aim of the current investigation is to develop oral once daily sustained release matrix tablets of risperidone, that match with theoretical drug release profile. The interaction studies of polymer and drug with FTIR revealed no interference, this made an account for usage of both hydrophilic and hydrophobic polymers in different combinations for direct compression of tablet. The evaluation of physical properties like angle of repose, bulk density, compressibility index, hausner ratio and appearance, dimensions, weight variation, hardness, friability, drug content, in vitro drug release were carried out for both powdered blend and compressed tablet respectively, and are in acceptable limit. Results of dissolution studies indicated that formulation containing 50% HPMC K100 and 27% sodium carboxy methylcellulose was the most successful formulation which was evidenced by similarity (f2) and dissimilarity (f1) factors. The formulated risperidone tablets followed first order release kinetics and Higuchi diffusion was the dominant mechanism of drug release, resulting in regulated and complete release within 24 hours. Swelling studies supported the mechanism of drug release. Risperidone is an atypical antipsychotic drug available in market as 0.5,1,4,6 and 8mg as conventional tablet with 16mg maximum dose per day. Very less number of sustain release formulations are not working out with dosage regimen provided. so in this work a novel approach to provide similar invitro release profile to that of developed theoretical drug release after oral administration is been targetted.
Loading....